课件：现代脂质三联治疗.ppt

Cerivastatin Clinical Data Part VI Change in LDL/HDL Ratio Datapool analysis, 8 weeks 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 Baseline 0.1mg 0.2mg 0.3mg 0.4mg 0.8mg n = 459 n = 636 n = 645 n = 1072 n = 732 LDL/HDL Ratio Data on file 50 45 40 35 30 25 20 15 10 5 0 25.6 0.7 46.2 40.2 35.5 32.0 % Change in LDL/HDL Ratio Datapool analysis, 8 weeks % Change in LDL/HDL Ratio Placebo 0.1mg 0.2mg 0.3mg 0.4mg 0.8mg Data on file Baseline LDL/HDL ratio After 8 weeks % of respondents ? 5 ? 5 12.3 ? 3 69.9 ? = 3 18.1 ? 3 - ? = 5 ? 5 0.2 ? 3 11.4 ? = 3 88.5 ? = 3 ? 3 0.5 ? = 3 99.5 LDL/HDL Responder Rates 0.4 mg responder rate at 8 weeks (n = 941) Data on file Baseline after 8 weeks 5 High CHD risk Medium CHD risk Low CHD risk 8% 60% 32% 90% 9% 1% 3-5 3 LDL / HDL Moving patients into the safety area after 8 weeks (n = 187) Reaching Target with LDL/HDL Ratio Reduction OSE et al. Curr Med Res Opinion 2000; 16 (2):80-87 LDL-C (mean % change from baseline after 24 weeks) 10 -40 -30 -20 -10 0 -50 -44.4% Men ( n = 200) Women ( n = 102) -37.0% LDL Cholesterol Reduction From Baseline OSE et al. Curr Med Res Opinion 1999; 15 (3): 231-43 LDL Reduction with 0.4 mg of Cerivastatin 90 80 70 60 50 40 30 20 10 0 29.7 87.4 70.7 49.5 ? 30 ? 35 ? 40 ? 45 Cumulative % of respondents LDL Responder Rates with 0.4 mg LDL % reduction rates in patients aged 60 to 65 years (n = 156) Data on file 0,0 2,0 4,0 6,0 8,0 10,0 12,0 14,0 16,0 18,0 50 40 30 HDL baseline HDL Responder Rates 50 % HDL increase Data on file 0.4 mg responder rate at 8 weeks 6.5 10.3 17.9 8.2 90 80 70 60 50 40 30 20 10 0 ? 10 23.3 9.3 81.4 65.1 55.8 ? 20 ? 30 ? 40 ? 50 TG responder rates for 0.4 mg TG % reduction rates from baseline ? 300 mg/dl at 8 weeks ( n = 43) Cumulative % of respondents Data on file Triglyceride mean % change from baseline after 8 weeks -20 -10 0 -30 -40 5 placebo 0.